Pfizer Inc vs Trade Desk Inc — how do they compare? Pfizer Inc trades at $27.9 (market cap $158.39B), while Trade Desk Inc trades at $13.92 (market cap $6.59B). The key difference: Pfizer Inc is far larger — about 24× Trade Desk Inc's market cap, and Pfizer Inc pays a 6.19% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| PFE | TTD | |
|---|---|---|
Market Cap | $158.39B | $6.59B |
Volume | 29,869,932 | — |
Sector | Health | Technology |
52-Week High | $29.02 | $54.13 |
52-Week Low | $23.60 | $13.03 |
Enterprise Value | $209.89B | $5.54B |
Dividend Yield | 6.19% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
The Trade Desk (TTD) trades at $14.02, down 2.84% amid bearish technical signals and recent earnings misses. The stock faces headwinds from slowing revenue growth (3% in Q2 2026) and a 15% workforce reduction announced in September 2026. Despite solid profitability margins (net margin 13.61%) and reasonable valuation (P/E 16.69), negative cash flow trends and competitive pressures weigh on sentiment. Technical indicators show resistance at $15 with support at $13-14, while analyst consensus remains mixed with a $14.07 price target.
Outlook: TTD's long-term ad-tech positioning and AI innovations (Kokai Zuma) offer growth potential, but near-term execution risks and macro ad demand softness pose challenges. Investors should monitor Q3 earnings and restructuring efficacy for catalysts. Risks include heightened competition and reliance on digital ad spending cycles.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →